Teva Investigational Site 563

Bradejov

0 studies enrolling now · 2 studies all time

What they study most

Eosinophilic Asthma

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma — Completed
• Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma — Stopped early